The Company has traditionally maintained incentive compensation plans that include provision for the issuance of equity-based awards. The Company established the 2008 Omnibus Equity Incentive Compensation Plan in 2008 (the “2008 Plan”) and has outstanding awards that were issued under the 2008 Plan. Subsequently, the 2008 Plan expired in 2018 and the Company established a new plan, the 2018 Omnibus Equity Incentive Plan (the “2018 Plan”) during the third fiscal quarter of 2018, pursuant to shareholder approval. Future awards will be issued under the 2018 Plan. Currently, the maximum number of shares available for issuance under the 2018 Plan is 900,000. The Company, in its annual proxy statement filed with the United States Securities and Exchange Commission on December 17, 2021, for the Company’s 2022 Annual Meeting of Shareholders to be held on February 9, 2022, submitted a proposal for shareholder approval on an amendment to increase the number of shares available for issuance under the 2018 Plan from 900,000 to 1,050,000.

Stock-based compensation is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the requisite service period (generally the vesting period of the grant). The Company recognizes the impact of forfeitures as forfeitures occur.

Our net income for the quarters ended December 28, 2021 and December 29, 2020 includes $95,000 and $61,000, respectively, of compensation costs related to our stock-based compensation arrangements.

The Company measures the compensation cost associated with stock option awards by estimating the fair value of the award as of the grant date using the Black-Scholes pricing model. The Company believes that the valuation technique and the approach utilized to develop the underlying assumptions are appropriate in calculating the fair values of the Company’s stock options and stock awards granted during the quarter ended December 28, 2021. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by the employees who receive equity awards.

During the quarter ended December 28, 2021, the Company granted 80,000 incentive stock options to its Chief Executive Officer, from available shares under its 2018 Plan, with an exercise price of $5.20 per share and a per share weighted average fair value of $2.65. These options were granted pursuant to the Chief Executive Officer’s Second Amended and Restated Employment Agreement dated December 24, 2020.

During the quarter ended December 29, 2020, the Company granted 90,000 incentive stock options to its Chief Executive Officer, from available shares under its 2018 Plan, with an exercise price of $2.33 per share and a per share weighted average fair value of $1.24. These options were granted pursuant to the Chief Executive Officer’s Second Amended and Restated Employment Agreement dated December 24, 2020.

In addition to the exercise and grant date prices of the stock option awards, certain weighted average assumptions that were used to estimate the fair value of stock option grants are listed in the following table:

	Quarter Ended December 28, 2021 Incentive and Non-Qualified Stock Options		Quarter Ended December 29, 2020 Incentive and Non-Qualified Stock Options

Expected term (years)		4.5	4.5
Expected volatility		61.3%	67.6%
Risk-free interest rate		0.9%	0.3%
Expected dividends		-	-

We estimate expected volatility based on historical weekly price changes of our common stock for a period equal to the current expected term of the options. The risk-free interest rate is based on the United States treasury yields in effect at the time of grant corresponding with the expected term of the options. The expected option term is the number of years we estimate that options will be outstanding prior to exercise considering vesting schedules and our historical exercise patterns.

Table of Contents

The following table summarizes stock option activity for the quarter ended December 28, 2021 under all plans:

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Yrs)

Outstanding at beginning of year		443,815		$	3.63
Options granted		80,000		$	5.20
Options exercised		(5,000	)	$	1.31
Outstanding December 28, 2021		518,815		$	3.89	5.7
Exercisable December 28, 2021		376,732		$	3.56	5.4

As of December 28, 2021, the aggregate intrinsic value of the outstanding and exercisable options was $393,000 and $369,000, respectively. Only options whose exercise price is below the current market price of the underlying stock are included in the intrinsic value calculation.

As of December 28, 2021, the total remaining unrecognized compensation cost related to non-vested stock options was $265,000 and is expected to be recognized over a weighted average period of approximately 1.7 years.

There were 5,000 stock options exercised that resulted in an issuance of 5,000 shares during the quarter ended December 28, 2021 with proceeds of approximately $6,000. There were 7,984 stock options exercised that resulted in an issuance of 7,984 shares during the quarter ended December 29, 2020 with proceeds of approximately $13,000.

Restricted Stock Units

During the quarters ended December 28, 2021 and December 29, 2020, there were no restricted stock units granted. A summary of the status of non-vested restricted stock as of December 28, 2021 is presented below.

	Shares			Grant Date Fair Value Per Share

Non-vested shares at beginning of year		61,952		$1.54 to $3.95
Vested		(15,616	)	$3.95
Non-vested shares at December 28, 2021		46,336		$1.54

As of December 28, 2021, there was $22,000 of total unrecognized compensation cost related to non-vested restricted stock. This cost is expected to be recognized over a weighted average period of approximately 0.7 years.

Restricted and Unrestricted Common Stock Awards

During the quarter ended December 28, 2021 there were 9,256 unrestricted shares of common stock granted to directors of the Company. These shares had a grant date fair value of $4.35 per share and resulted in the recognition of $40,000 of stock-based compensation expense. No grants of restricted or unrestricted common stock were made during the quarter ended December 29, 2020.